IL17A and rheumatoid arthritis: In fact, clinical trials using a humanized anti-IL-17 monoclonal antibody added to oral disease-modifying anti-rheumatic drugs, demonstrated improved signs and symptoms of RA, indicating the therapeutic potential of IL-17-directed strategies (Genovese et al., 2010).